^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
Published date:
06/10/2022
Excerpt:
We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547...administered with anastrozole or letrozole in estrogen receptor positive metastatic breast cancer patients... Two partial responses (PR) and 19 stable disease (SD) patients were observed at the 12-week time point. At 28 weeks, according to centrally reviewed Response Evaluation Criteria in Solid Tumours (RECIST) criteria, five PR and 8 SD patients were observed in 50 assessable cases.
Secondary therapy:
letrozole; anastrozole
DOI:
10.1038/s41467-022-30666-0
